Please use this identifier to cite or link to this item:
|Title:||Perioperative IFN-a to avoid surgically induced immune suppression in colorectal cancer patients|
|Publisher:||Murcia : F. Hernández|
|Related subjects:||CDU::6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncología|
|Abstract:||Surgical treatment of colorectal cancer is associated with postoperative immunosuppression, which might facilitate dissemination of tumor cells and outgrowth of minimal residual disease/(micro) metastases. Minimal residual disease has been shown to be of prognostic relevance in colorectal cancer. Therefore, stimulation of (anti-tumor) immune responses may be beneficial in the prevention of metastases formation. Important anti-tumor effector cells, which serve this function, are natural killer (NK) cells, CD8+ lymphocytes (CTL), dendritic cells (DC) and macrophages. In this review the immunomodulating properties of IFN-a are discussed, with a particular focus on perioperative stimulation of immune function in cancer patients. IFN-a is known to enhance innate immune functions such as stimulation of NK cells, transition from innate to adaptive responses (activation of DC) and regulating of CD8+ CTL activity and memory. Moreover, it exerts direct antitumor effects by regulating apoptosis and cell cycle. In several clinical trials, perioperative administration of IFN-a has indeed been shown to improve T cell responsiveness, prevent impairment of NK cell cytotoxicity and increase expression of activation markers on NK, T and NKT cells. In a clinical pilot study we showed in colorectal cancer patients that received perioperative IFN-a enhanced activation markers on T cells and NK cells, combined with betterpreserved T cell function as indicated by phytohemaggluttinin skin tests. In the liver of these patients significantly more CD8+ T cells were found. In conclusion, IFN-a provides an effective adjuvant in several forms of cancer and improves several postoperative immune functions in perioperative administration. However, larger clinical trials are necessary to investigate effects on disease-free and overall survival.|
|Primary author:||Oosterling, S.J.|
van der Bij, G.J.
van Egmond, M.
van Leeuwen, P.A.M.
|Published in:||Histology and histopathology|
|Number of pages / Extensions:||8|
|Appears in Collections:||Vol.21, nº 7 (2006)|
Files in This Item:
|Perioperative IFNa to avoid surgically induced immune suppression.pdf||4,58 MB||Adobe PDF||View/Open|
Items in Digitum are protected by copyright, with all rights reserved, unless otherwise indicated.